- Home
- VTGN vs QNCX Comparison
VTGN vs QNCX Comparison
Compare VTGN & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTGN
- QNCX
- Stock Information
- Founded
- VTGN 1998
- QNCX 2012
- Country
- VTGN United States
- QNCX United States
- Employees
- VTGN N/A
- QNCX N/A
- Industry
- VTGN Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VTGN Health Care
- QNCX Health Care
- Exchange
- VTGN Nasdaq
- QNCX Nasdaq
- Market Cap
- VTGN 124.3M
- QNCX 100.4M
- IPO Year
- VTGN N/A
- QNCX 2019
- Fundamental
- Price
- VTGN $4.05
- QNCX $1.86
- Analyst Decision
- VTGN
- QNCX Strong Buy
- Analyst Count
- VTGN 0
- QNCX 6
- Target Price
- VTGN N/A
- QNCX $8.00
- AVG Volume (30 Days)
- VTGN 666.9K
- QNCX 438.0K
- Earning Date
- VTGN 11-06-2025
- QNCX 11-12-2025
- Dividend Yield
- VTGN N/A
- QNCX N/A
- EPS Growth
- VTGN N/A
- QNCX N/A
- EPS
- VTGN N/A
- QNCX N/A
- Revenue
- VTGN $646,000.00
- QNCX N/A
- Revenue This Year
- VTGN $10.19
- QNCX N/A
- Revenue Next Year
- VTGN $705.79
- QNCX N/A
- P/E Ratio
- VTGN N/A
- QNCX N/A
- Revenue Growth
- VTGN N/A
- QNCX N/A
- 52 Week Low
- VTGN $1.90
- QNCX $0.72
- 52 Week High
- VTGN $4.39
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- VTGN 64.68
- QNCX 54.40
- Support Level
- VTGN $3.82
- QNCX $1.82
- Resistance Level
- VTGN $4.33
- QNCX $2.04
- Average True Range (ATR)
- VTGN 0.29
- QNCX 0.17
- MACD
- VTGN 0.01
- QNCX 0.01
- Stochastic Oscillator
- VTGN 66.75
- QNCX 44.65
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.